Also trades as LILY34.SA, LLY.DE.
LLY
Strong BuyPremium GrowerAI pickEli Lilly and Company · Healthcare · United States · $1.0T cap · $2.7B/day traded
$1,182.62 +0.3% · close 12 Oct · scored 14 Oct
Premium Grower: Strong business with the market behind it, priced at a premium.
Read our full research report on LLY (Apr 2026), freeReport expected 29 Oct: the next-year EPS estimate has risen 6.3% over the last 13 weeks.
As of 14 Oct 2026, MoatMap's StockRank for Eli Lilly and Company (LLY) is 82/100, ranked against 24,000+ stocks in 35 markets (Quality 80, Value 20, Momentum 77, each scored against its sector).
Does StockRank work? Each month we publish how every decile did, whichever way it went. See the record →
Eli Lilly leads the fastest-growing drug category in the world, with visible real-world demand for Zepbound and Mounjaro. Its pipeline keeps extending that lead: a higher dose of Zepbound has widened its weight-loss advantage over Wegovy, the oral pill Foundayo has shown greater weight loss, and the triple-agonist retatrutide delivered substantial weight loss and blood sugar reduction in trials. Quality is high, the business funds its growth from its own cash flow, and a buyback is active. The shares are expensive on current numbers, so the case depends on earnings continuing to grow into the valuation as manufacturing scale and new oral and next-generation drugs broaden the patient base.
ABOUT ELI LILLY AND COMPANY
Read
Eli Lilly and Company is a global pharmaceutical powerhouse that discovers, develops, manufactures, and markets innovative medicines across key therapeutic areas such as diabetes, oncology, immunology, and neuroscience. Its wide competitive moat is built on a robust R&D pipeline, extensive patent protection for its blockbuster drugs, and a well-established global sales and distribution network. Eli Lilly is a leading innovator, recently achieving significant market success in diabetes and obesity treatments.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 28.5B | 34.1B | 45.0B | 65.2B | 31.7% | 79.7B | 88.5B | 102.4B | 25.3% |
| EPS | 6.57 | 5.83 | 11.80 | 23.07 | 52.0% | 29.79 | 34.08 | 42.95 | 36.5% |
| Shares | 950.2M | 899.4M | 897.5M | 894.8M | -5.8% | 891.7M | — | — | — |
| Debt | 16.2B | 25.2B | 33.6B | 42.5B | 37.8% | 54.9B | — | — | — |
| Equity | 10.6B | 10.8B | 14.3B | 26.5B | 35.6% | — | — | — | — |
| Op CF | 7.6B | 4.2B | 8.8B | 16.8B | 30.4% | 28.1B | — | — | — |
| Inv CF | -3.8B | -7.2B | -9.3B | -11.0B | — | — | — | — | — |
| Fin CF | -5.4B | 3.5B | 1.2B | -2.2B | — | — | — | — | — |
Above its 200-day average and 9% below its 52-week high.
Calmer than 63% of stocks we rank over the past year (35% a year).
How this is worked out
StockRank judges the business. The price check reads only the chart: it is the price side of the Momentum score, in words.
The rules: Still falling is a new 52-week low in the last two weeks, at least 25% below the high. Finding a floor is no new low since. Turning up is 20 or more trading days without a new low, at least 10% off it, and back above a rising 50-day average. In an uptrend is above the 200-day average and within 15% of the high.
In 2,112 US drawdowns since 2001, buying while the price was still falling was followed by a further 20% drop 42% of the time. Waiting for a turn like this one cut that to 33%, at about 7% higher prices and with no better returns. Part of that cut is simply not buying: 13% of falls never turned, and waiting kept those out. Among turns that were bought, 38% still fell another 20%, and 33% of turns were followed by a new low within six months. The benefit was largest in crashes such as 2008 and 2020.
What it measures: day-to-day price moves over the past year, as a yearly figure, ranked against every stock we cover. Very calm under 20% a year, Calm 20 to 30%, Average 30 to 40%, Bumpy 40 to 55%, Very bumpy above that.
What we found: across about 13,500 stocks in 34 markets (2002 to 2025), past swings were a good guide to the next year's, and bumpier stocks fell further. How much further changed too much between eras to put a number on it.
Calm is not safe: a calm stock can still slide steadily.
Rules fixed before any data was fetched. Describes the chart, not a recommendation.
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of LLY are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| LLY | Eli Lilly and Company(you) | $1.0T | 82 | Strong Buy |
| JNJ.DE | Johnson & Johnson | $625.3B | 84 | Strong Buy |
| ABBV | AbbVie Inc. | $468.4B | 88 | Strong Buy |
| 6MK.DE | Merck & Co., Inc. | $357.7B | 80 | Strong Buy |
| NVS | Novartis AG | $271.3B | 80 | Strong Buy |
| RO.SW | Roche Holding AG | $362.7B | 93 | Strong Buy |
| AZN.L | AstraZeneca PLC | $255.1B | 76 | Buy |
| GIS.DE | Gilead Sciences, Inc. | $185.7B | 79 | Buy |
| AMGN | Amgen Inc. | $219.5B | 91 | Strong Buy |
| NVO | Novo Nordisk A/S | $168.6B | 78 | Buy |
Peer medians: ROE 2.9% · P/E 23.9x · Gross margin 53.8%
Company Deep Dive
Read the full research report: business segments breakdown, earnings transcripts review, management credibility analysis, competitive landscape, and scenarios.